PriceSensitive

Next Science (ASX:NXS) appoints new Chief Executive and Managing Director

ASX News, Health Care
ASX:NXS      MCAP $91.88M
16 June 2023 12:00 (AEST)
Next Science (ASX:NXS) - Outgoing CEO and Managing Director, Judith Mitchell

Source: Next Science

Next Science (NXS) has appointed Harry Thomas Hall IV (I.V.) as its newest Managing Director and Chief Executive Officer.

I.V. will begin in the role from July 10, on a total fixed remuneration contract of US$450,000 (A$653,000) per annum.

For more than 25 years, I.V. has worked in the global medical device industry, holding a number of roles across product development, global strategic marketing, commercial operations and sales leadership.

He is also the president of Trauma, Extremities, Craniomaxillofacial and Animal Health, responsible for the global portfolio and execution strategy for a US$3.2 billion platform (A$4.64 billion).

“I.V. is a respected leader in the healthcare industry marrying a rare blend of scientific, clinical and commercial skill and experience,” Next Science Chair Professor Mark Compton AM said.

“I.V. has a proven track record in building successful businesses, and just as importantly, a successful organisational culture.”

Mr Compton also thanked outgoing CEO Judith Mitchell for her contribution to the company and its development of XBIO.

“Judith has built a strong presence for Next Science in the US in particular, led the company through its ASX listing and built a team focused on commercial success,” Mr Compton said.

Next Science is now focusing on commercialising its XBIO technology which aim to reduce the impact of biofilm-based infections.

Judith Mitchell will remain with the company until the end of July to aid in a smooth handover.

Shares in NXS rose 4.72 per cent to 55.5 cents at midday AEST.

Related News